POLYMED Poly Medicure Q3 FY26 results (Oct–Dec 2025) and concall
Poly Medicure is undergoing a strategic transition from low-technology products to high-complexity, high-growth segments like cardiology and orthopedics. Despite headwinds in the export market and aggressive Chinese dumping, the company achieved double-digit consolidated revenue growth, largely aided by recent European acquisitions. Management is focused on the domestic private market and high-end R&D products to drive future margins and market share.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 16.5%, net profit down 16.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 420 | 424 | 441 | 403 | 444 +6% | 494 +17% |
| EBITDA | 115 | 114 | 119 | 106 | 115 +0% | 111 −3% |
| Net profit | 87 | 85 | 92 | 93 | 92 +6% | 71 −16% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
